In recent trading, Lexicon Pharmaceuticals Inc (LXRX) stock price has shown some volatility, fluctuating -33.33% over the last five trades and -22.62% over the past 30 trades. This represents a ...

After multiple rejections, Lexicon Pharmaceuticals is inching toward an FDA decision date next month for its adjunct type 1 ...

Shares of Lexicon Pharmaceuticals tanked nearly 33.6% as of 11:30 am ET after the drug company’s sotagliflozin drug candidate received a negative vote by a US Food and Drug Administration (FDA) panel, ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 3.44% of ...

A simultaneous webcast will be available in the “Events” section of the Lexicon website at and a recording of the webcast will be available for two weeks following the original on-demand date. About ...

Lexicon Pharmaceuticals (NASDAQ:LXRX) lost ~39% in the morning hours on Friday following a trading halt in the previous ...

Independent advisers to the U.S. Food and Drug Administration on Thursday voted against recommending Lexicon Pharmaceuticals' ...

While an FDA advisory committee saw signals of efficacy for Lexicon Pharmaceuticals’ sotagliflozin, the panel of external ...

Lexicon Pharmaceuticals LXRX has been analyzed by 11 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments ...

Independent advisers to the FDA voted against recommending Lexicon Pharmaceuticals‘ add-on treatment to insulin therapy for ...

THE WOODLANDS, Texas, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Jefferies London Global Healthcare Conference.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...